secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001299130-25-000165
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio Q3 revenue $38.4M, net loss narrows to $38M; consumables hit record $21.3M
--------------------------------------------------------------------------------

- GAAP net loss $38.0M ($0.13 loss per share) vs $60.7M ($0.22) YoY; non-GAAP net loss $36.8M ($0.12).
- Consumable revenue record $21.3M (+15% YoY); instrument revenue $11.3M (down 33% YoY).
- Non-GAAP gross margin improved to 42% from 33% YoY; operating expenses cut to $53.9M from $62.4M.
- Revio systems shipped 13 (vs 22); Vega systems shipped 32; cash and investments $298.7M.
- Launched SPRQ-Nx chemistry to reduce sequencing costs up to 40%; Sequel II CNDx approved in China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000129913025000165/0001299130-25-000165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000129913025000165/pacb-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001299130-25-000165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer